Xeroderma Pigmentosum (XP) is a rare genetic disorder that affects the skin and eyes. It is caused by a genetic mutation that results in an inability to repair damage to the DNA caused by exposure to ultraviolet radiation from the sun. People with XP are at increased risk for developing skin cancer, as well as other types of cancers. XP is an incurable disorder, but early diagnosis and management can help reduce the risk of developing skin cancer. In this article, we will explore the causes, symptoms, diagnosis, and treatment of XP.
Xeroderma Pigmentosum (XP) is a rare genetic disorder that affects the skin and eyes. It is caused by a genetic mutation that results in an inability to repair damage to the DNA caused by exposure to ultraviolet radiation from the sun. People with XP are at increased risk for developing skin cancer, as well as other types of cancers. XP affects both males and females of all ethnicities and is estimated to affect 1 in every 250,000 people.
XP is caused by a mutation in one of eight genes that are responsible for repairing DNA damage caused by ultraviolet radiation. This mutation is inherited in an autosomal recessive manner, meaning that both parents must have a copy of the mutated gene in order for their child to be affected. If only one parent has the mutated gene, the child will be a carrier, but will not be affected by the disorder.
The symptoms of XP vary from person to person, but the most common symptoms are: • Extremely sensitive skin that burns and itches when exposed to the sun • Blistering of the skin when exposed to the sun • Freckling on the face, neck, and arms • Premature aging of the skin • Eye problems such as dry eyes, sensitivity to light, and vision loss • A weakened immune system • An increased risk of developing skin cancer
XP is typically diagnosed through a combination of physical exams, family history, and genetic testing. During a physical exam, a doctor may look for signs of sun damage such as freckling, blistering, and premature aging of the skin. A family history of XP may also be taken into consideration. Genetic testing can confirm a diagnosis of XP, as it can identify the mutation in the genes responsible for repairing DNA damage.
Currently, there is no cure for XP, but there are treatments that can help reduce the risk of developing skin cancer. These treatments include: • Avoiding sun exposure: People with XP should avoid direct sun exposure as much as possible. This includes wearing protective clothing, hats, and sunscreen with SPF 30 or higher. • Phototherapy: Phototherapy is a type of light therapy that can help reduce the risk of skin cancer. It involves exposing the skin to artificial ultraviolet light under the supervision of a doctor. • Topical medications: Topical medications, such as creams and gels, can help reduce the risk of skin cancer. • Surgery: In some cases, surgery may be necessary to remove any cancerous growths.
Xeroderma Pigmentosum (XP) is a rare genetic disorder that affects the skin and eyes. It is caused by a genetic mutation that results in an inability to repair damage to the DNA caused by exposure to ultraviolet radiation from the sun. People with XP are at increased risk for developing skin cancer, as well as other types of cancers. While there is no cure for XP, early diagnosis and management can help reduce the risk of developing skin cancer. Treatment options include avoiding sun exposure, phototherapy, topical medications, and surgery.
1.
A BRAF V600E mutation-positive intrathoracic synovial sarcoma is reported by researchers.
2.
No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer
3.
Innovative oncology therapeutics are being created in collaboration between Moderna and Immatics.
4.
An inoperable locally advanced NSCLC trial dubbed "Practice Changing".
5.
CDC Alerts on Dramatic Rise in Human Parvovirus B19
1.
All You Need To Know About Partial Thromboplastin Time (PTT) Test
2.
Machine Learning in Genomic Analysis for Early Lung Cancer Detection: Key Advances and Insights
3.
Survivin as a Key Regulator in Gynecological Cancers: Therapeutic and Prognostic Implications
4.
Rasburicase-Linked Methemoglobinemia in HCC: Risks, Mechanisms, and Management
5.
Unleashing the Inner Predator: Reprogramming Macrophages to Conquer Cancer Immunotherapy
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
Navigating the Complexities of Ph Negative ALL - Part IV
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
4.
Newer Immunotherapies for Myeloma- A Comprehensive Overview
5.
Navigating the Complexities of Ph Negative ALL - Part XII
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation